Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
Want to see CNTB full AI Analyst Report?
CNTB Stock Chart & Stats
$2.81
$0.04(3.94%)
At close: 4:00 PM EST
$2.81
$0.04(3.94%)
Day’s Range― - ―
52-Week Range$0.85 - $3.82
Previous CloseN/A
Volume1.98K
Average Volume (3M)97.97K
Market Cap
$133.48M
Enterprise Value$119.12M
Total Cash (Recent Filing)$44.34M
Total Debt (Recent Filing)$690.00K
Price to Earnings (P/E)―
Beta-0.26
Next Earnings
Sep 15, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding62,963,852
10 Day Avg. Volume111,495
30 Day Avg. Volume97,966
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.74
Price to Sales (P/S)2452.52
P/FCF Ratio-3.04
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue2.48K
Enterprise Value/Gross Profit2.48K
Enterprise Value/Ebitda-4.32
Forecast
1Y Price Target
$7.25Price Target Upside158.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-7.14
Revenue Forecast (FY)$35.48M
Bulls Say, Bears Say
Bulls Say
Low Debt / Balance Sheet StrengthVery low reported debt materially reduces interest burden and insolvency risk versus highly levered peers. For a clinical-stage biotech this strengthens the company's ability to allocate capital to R&D and to negotiate financing or partnerships from a position of lower leverage, supporting multi‑quarter program execution.
New Financing Extends RunwayThe $20.2M private placement meaningfully extends operational runway to mid/late 2027, reducing near-term refinancing pressure. That durable liquidity buffer allows management to progress pivotal activities, engage regulators, and pursue Phase 3 planning without immediate capital markets dependency.
De-risking Clinical Readouts And Phase 3 PathwayA clean DMC interim review and favorable early clinical signals reduce program-level safety risk and support regulatory dialogue. This materially de-risks the lead respiratory candidate and preserves optionality to pursue Phase 3, a structural value driver if efficacy and safety are confirmed.
Bears Say
Persistent Cash Burn And Negative Free Cash FlowSustained, large negative operating and free cash flow require repeated external financing to sustain development. Over the medium term, continued cash burn constrains program breadth, increases dilution or debt risk, and raises execution vulnerability if capital access becomes restricted.
No Recurring Revenue And Widening LossesAbsence of recurring product revenue means long-term viability hinges entirely on clinical success or deals. Large, widening losses increase dependence on capital markets or partners; without commercialization milestones this remains a structural profitability risk over the next several quarters.
Eroding Equity And Assets Reduce Financial FlexibilityMaterial declines in equity and assets shrink the balance sheet cushion, limiting borrowing capacity and the firm's ability to withstand trial setbacks. This reduces strategic optionality, increases likelihood of future dilutive financings, and amplifies downside if programs encounter delays or failures.
Connect Biopharma Holdings News
CNTB FAQ
What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $0.85 and its highest was $3.82 in the past 12 months.
What is Connect Biopharma Holdings’s market cap?
Connect Biopharma Holdings’s market cap is $133.48M.
When is Connect Biopharma Holdings’s upcoming earnings report date?
Connect Biopharma Holdings’s upcoming earnings report date is Sep 15, 2026 which is in 92 days.
How were Connect Biopharma Holdings’s earnings last quarter?
Connect Biopharma Holdings released its earnings results on May 12, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of N/A by $0.05.
Is Connect Biopharma Holdings overvalued?
According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
Does Connect Biopharma Holdings pay dividends?
Connect Biopharma Holdings does not currently pay dividends.
What is Connect Biopharma Holdings’s EPS estimate?
Connect Biopharma Holdings’s EPS estimate is -0.31.
How many shares outstanding does Connect Biopharma Holdings have?
Connect Biopharma Holdings has 62,963,852 shares outstanding.
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Connect Biopharma Holdings reported an EPS of $0.05 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 14.53%.
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
Currently, no hedge funds are holding shares in CNTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Connect Biopharma Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.25 (158.01% Upside)
$7.25 (158.01% Upside)
Insider Transactions
Bought Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.51%
12-Months-Change
Fundamentals
Return on Equity
-49.43%
Trailing 12-Months
Asset Growth
-35.19%
Trailing 12-Months
Company Description
Connect Biopharma Holdings
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
CNTB Stock 12 Month Forecast
Average Price Target
$7.25
▲(158.01% Upside)
Technical Analysis
Scinai Immunotherapeutics
―
GT Biopharma
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Ownership Overview
21.28% Insiders
0.04% Mutual Funds
16.42% Other Institutional Investors
62.27% Public Companies and
Individual Investors